Composition for improving bone density and application thereof

Abstract

The invention discloses a composition for improving bone density and application thereof, and belongs to the technical field of food. According to the invention, the 1, 3-dioleic acid-2-palmitin, the osteopontin and the oligosaccharide are compounded for use, and the components interact to promote mutual absorption and utilization, so that the growth and development of bones in the growth period of infants are improved, the mineral content and the bone mineral density of the bones are increased, the health of the bones is promoted, and the composition is safe and free of side effects. And by optimizing the variety of the oligosaccharide, the compound use of the galactooligosaccharide and the 2 '-fucosyllactose is found to be capable of better improving the growth and development of bones in the growth period of the infants.

Description

Technical Field

[0001] The invention belongs to the technical field of food, and in particular relates to a composition for improving bone density and application thereof. Background Art

[0002] The development of the human skeletal system is a long-term dynamic and continuous process from the early embryonic stage to the mature stage. The basic way of human bone formation is the formation and absorption of bone tissue. In the process of bone tissue formation, osteoblasts first secrete bone gelatin fibers and bone matrix to form osteoid. After the osteoid is formed, the matrix ossification is completed by the deposition of matrix apatite to become bone tissue. Later, new osteoblasts continue to form osteoid on the surface of the formed bone tissue.

[0003] And deposit calcium salts, which are converted into bone. This continuous process makes the bone tissue grow continuously during the embryonic period and the postnatal growth and development period. Osteoblasts secrete various bone cell matrix proteins and control the mineralization process of bone matrix. Therefore, the occurrence, proliferation, differentiation and maturation of osteoblasts are closely related to the normal growth and development of bones. If any of these links is damaged, bone growth disorders will occur. 60% of the weight of mature bones is minerals, mainly composed of calcium salts. The amount of mineral deposition in bones is called bone mineral content. The bone mineralization process of human bones is parallel to the increase in height. Therefore, most of the accumulation of bone mass occurs in children and adolescents, especially in the first year after birth and during puberty, when the minerals of bone matrix are deposited the most. When height stops growing, bone mineralization continues at a rate of 8.5% per year until the age of peak bone mass, which is about 30 years old. After reaching peak bone mass, bone formation and bone resorption remain balanced. With age and endocrine changes, the rate of bone resorption increases and bone mass decreases. The peak bone mass during each person's bone maturity period is different, and high-density peak bone mass can effectively prevent age-related bone calcium loss.

[0004] An increase in peak bone mass will reduce the risk of osteoporosis in later life. A 10% increase in maximum bone mass during growth will reduce the risk of osteoporotic fractures by 50%. Therefore, improving bone growth through breast milk and dietary nutrition in the early stages of life, especially in infancy, childhood, and adolescence, may play a huge role in bone health later in life. Increasing peak bone mass during growth is important for maintaining adolescent bone health.

[0005] OPO structured lipids (1,3-dioleoyl-2-palmitoyl triglyceride) are the main triglycerides in breast milk, accounting for about 12% of the total triglycerides. Palmitic acid (16:0) is the main saturated fatty acid, most of which is esterified at the sn-2 position (in the middle), while oleic acid is the main unsaturated fatty acid, most of which is esterified at the sn-1 and sn-3 bonds (outside) of the triglyceride. This structured lipid enables infant formula to mimic the composition and structure of fat in breast milk. Structured triglycerides are synthesized by enzyme catalysis and contain 17%-25% palmitic acid, of which more than 40% is esterified at the sn-2 position.

[0006] Studies (journal articles: "Feeding premature newborn infants palmitic acid inamounts and stereoisomeric position similar to that of human milk: Effects on fat and mineral balance", Carnielli, VP, et al., "The American journal of clinicalnutrition", 1995, pp. 1037-1042; "The clinical effect of a new infant formula interminfants with constipation: a double-blind, randomized cross-over trial", Bongers MEJ, et al., "Nutrition Journal", 2007, pp. 8-14) show that OPO has the effects of enhancing fatty acid and mineral absorption, reducing constipation, increasing bone strength, and reducing inflammation. Compared with infants and young children who consume ordinary infant formula milk powder, infants and young children who consume formula milk powder with high OPO content have higher absorption rate of bone minerals, lower stool hardness, and fewer saponification products of fatty acids in stool, which are similar to the bone minerals, stool hardness and fatty acid saponification of breastfed infants. The mechanism may be: 1) OPO is easily digested by infants and young children, and can promote the body's absorption of energy substances such as fatty acids; 2) OPO can promote the absorption of fat by infants; 3) OPO can promote the absorption of minerals (K, Na, Al, P, Ca, Mg) and vitamins necessary for the growth of infants and young children, promote the normal growth of the infant's bones and brain, maintain neuromuscular excitement, conduction of nerve impulses, and normal heart beat.

[0007] Osteopontin (OPN, osteopontin in breast milk is also called lactopontin, LPN) and oligosaccharides (2'-fucosyllactose, 3'-fucosyllactose, galacto-oligosaccharides, etc.) as effective active ingredients in breast milk can also regulate the growth and development of infants.

[0008] Based on this, the present invention provides a composition for improving bone density, which uses 1,3-dioleyl-2-palmitoyl triglyceride, osteopontin and oligosaccharides in combination, and improves the growth and development of bones in infants and young children during their growth period, increases bone density and promotes bone health through the mutual promotion effect between the components. Summary of the invention

[0009] The present invention aims at the problems existing in the prior art and provides a composition for improving bone density and its application. The present invention adopts 1,3-dioleyl-2-palmitoyl triglyceride, osteopontin and oligosaccharide for composite use, and promotes the absorption and utilization of each other through the interaction between the components, thereby improving the growth and development of bones in the growth period of infants and young children, increasing bone density and promoting bone health. And by optimizing the types of oligosaccharides, the effect can be further improved.

[0010] To achieve the above objectives, in a first aspect, the present invention provides a composition for improving bone density, comprising: 1,3-dioleyl-2-palmityl triglyceride, osteopontin and oligosaccharides.

[0011] In a preferred embodiment, the mass ratio of 1,3-dioleyl-2-palmitoyl triglyceride, osteopontin and oligosaccharide is 100-200:0.5-20:100, more preferably 100-200:0.5-10:100.

[0012] In a preferred embodiment, the oligosaccharide is galacto-oligosaccharide and 2'-fucosyllactose (2'-FL) in a mass ratio of 1-2:1.

[0013] In a preferred embodiment, the composition further comprises at least one of unsaturated fatty acids, vitamins, minerals, proteins, fats, carbohydrates, and functional additives.

[0014] In a preferred embodiment, the functional additive includes at least one of folic acid, niacin, pantothenic acid, biotin, choline, inositol, taurine, L-carnitine, and nucleotides.

[0015] In a preferred embodiment, the unsaturated fatty acid includes at least one of docosahexaenoic acid, eicosatetraenoic acid, linolenic acid, and α-linolenic acid.

[0016] In a preferred embodiment, the vitamins include vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B 12 , vitamin C and at least one of them.

[0017] In a preferred embodiment, the minerals include at least one of sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, iodine, chlorine, and selenium.

[0018] In a second aspect, the present invention provides the use of the aforementioned composition for improving bone density in the preparation of a product for promoting bone development.

[0019] In a preferred embodiment, the promoting bone development is increasing bone density.

[0020] In a preferred embodiment, the product is a food or a medicine.

[0021] In a preferred embodiment, the product includes nutritional supplements, solid beverages, and milk powder.

[0022] In a third aspect, the present invention provides a product for promoting bone development, comprising the aforementioned composition for improving bone density.

[0023] The beneficial effects of the present invention are:

[0024] 1. The present invention uses 1,3-dioleyl-2-palmitoyl triglyceride, osteopontin and oligosaccharides in combination, and through the interaction between the components, promotes the absorption and utilization of each other, improves the growth and development of bones during the growth period of infants and young children, increases bone mineral content and bone density, and promotes bone health.

[0025] 2. The present invention optimizes the types of oligosaccharides and finds that the combined use of galacto-oligosaccharides and 2'-fucosyllactose can better improve the growth and development of bones in infants and young children during their growth period.

[0026] 3. The composition for improving bone density of the present invention has no significant effect on the development of mice's organs, no side effects, and good safety. DETAILED DESCRIPTION

[0027] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

[0028] It should be noted that the raw materials used in the present invention are all ordinary commercially available products, and no specific limitation is imposed on their sources.

[0029] 1,3-Diolein-2-palmitin (OPO): Model InFat TM 7860, purchased from AAK SE;

[0030] Osteopontin (OPN): Model OPN-10, purchased from Arla Foods Ingredients;

[0031] Galactooligosaccharides (GOS): Model GOS, purchased from Royal FrieslandCampina;

[0032] 2'-Fucosyllactose (2'-FL), 3'-Fucosyllactose (3'-FL), 6'-Sialyllactose (6'-SL): Purchased from Glycom.

[0033] Preparation of the compositions of Examples 1-3 and Comparative Examples 1-4

[0034] The compositions of Examples 1-3 and Comparative Examples 1-4 are formulated as shown in Table 1:

[0035] Table 1

[0036]

[0037] Weigh the raw materials according to the formulation in Table 1 and mix them evenly to obtain the corresponding compositions.

[0038] Test Examples

[0039] 1. Animal grouping and feeding

[0040] Animals: 4-week-old male C56BL / 6 mice, weighing 18-20 g, provided by Shanghai SLAC Laboratory Animal Co., Ltd., license number: SCXK (Shanghai) 2017-0005.

[0041] Grouping and feeding: Sixty-four 4-week-old male C56BL / 6 mice were adaptively fed for one week (temperature 23±2°C, humidity 50±2%, 12-hour light-dark cycle). They were randomly divided into 8 groups, with 8 mice in each group. After one week of adaptation, the mice in Examples 1-3 and Comparative Examples 1-4 were gavaged with the corresponding compositions at a dose of 400 mg / kg per day, and the control group was fed freely. The above gavage was performed once a day, at 9-11 am every day, for 8 weeks.

[0042] 2. Whole body bone mineral density

[0043] Before oral administration (before intervention) and after the end of the experiment (after intervention), the whole-body bone density (BMD, mg / cm 2 ) detection, the results are shown in Table 2.

[0044] Table 2 Whole body bone density of mice in each group

[0045]

[0046] Note: * indicates that compared with the pre-intervention period, P < 0.05; ** indicates that compared with the pre-intervention period, P < 0.01; # Compared with the control group, P < 0.05; ## Δ indicates that compared with the control group, P < 0.01; Δ indicates that compared with Example 1, P < 0.05.

[0047] As can be seen from Table 2, the bone density of Example 1-3 groups after intervention was significantly improved compared with that before intervention, and was significantly improved compared with the control group; the degree of improvement in bone density in Example 1 was significantly higher than that in Comparative Example 1-4 groups. It can be seen that the specific type of oligosaccharide has a great influence on improving bone density, among which 2'-fucosyllactose can promote bone development and growth compared with 3'-fucosyllactose or 6'-sialyl lactose, and the use of oligosaccharides and 2'-fucosyllactose in combination can promote bone development and growth, and have higher bone density.

[0048] 3. Body weight and organ mass

[0049] During the experiment, the body weight of mice in each group was regularly monitored and analyzed; after the experiment, the mice were killed, dissected, and the weight of their relevant organs was weighed to calculate the organ / body weight ratio (heart-body ratio, liver-body ratio, kidney-body ratio, spleen-body ratio, in %). The results are shown in Table 3.

[0050] Table 3 Organ / body weight ratio of mice in each group

[0051] Group Heart-body ratio Liver to body ratio Kidney to body ratio Spleen to body ratio Control group 0.52±0.036 5.11±0.352 1.23±0.070 0.44±0.019 Example 1 0.54±0.041 5.14±0.323 1.23±0.057 0.45±0.023 Example 2 0.54±0.052 5.12±0.316 1.24±0.066 0.45±0.017 Example 3 0.53±0.039 5.09±0.289 1.23±0.068 0.44±0.016 Comparative Example 1 0.52±0.047 5.10±0.322 1.25±0.074 0.47±0.025 Comparative Example 2 0.53±0.055 5.13±0.367 1.24±0.078 0.48±0.029 Comparative Example 3 0.52±0.040 5.15±0.381 1.23±0.064 0.47±0.026 Comparative Example 4 0.53±0.046 5.12±0.333 1.25±0.081 0.47±0.031

[0052] As can be seen from Table 3, the difference in organ / body weight ratio between Example 1-3, Comparative Example 1-4 and the control group is very small and not significant. It can be seen that the compositions of Example 1-3 and Comparative Example 1-4 have no side effects and no adverse effects on the development of mice.

[0053] 4. Bone mineral testing

[0054] In the body weight and organ mass experiments, mice were killed, the femoral bones of the hind limbs were separated, and the bone mineral (calcium + zinc + magnesium) content of the epiphyseal bone of the left hind limb of the mice was measured using a two-dimensional scanning single-photon bone densitometer (BH-602, Beijing Nuclear Instrument Factory) in μg / g. The results are shown in Table 4.

[0055] Table 4 Bone mineral content in each group

[0056] Group Bone mineral content μg / g Control group 328.2±34.5 Example 1 <![CDATA[391.3±46.4 # ]]> Example 2 <![CDATA[386.1±49.2 # ]]> Example 3 <![CDATA[383.5±51.0 # ]]> Comparative Example 1 341.6±38.9* Comparative Example 2 352.7±41.1* Comparative Example 3 347.8±40.5* Comparative Example 4 339.2±36.6*

[0057] Note: # Indicates P<0.01 compared with the control group; * indicates P<0.05 compared with Example 1.

[0058] As can be seen from Table 4, the mineral content in the bones of the mice in Examples 1-3 was significantly higher than that in the control group and the comparative examples 1-5, indicating that the composition defined by the present invention is beneficial to increasing the mineral content in the bones. The increase in the mineral content in the bones is beneficial to promoting bone growth and improving bone density.

[0059] In summary, the composition of the present invention is beneficial to improving bone mineral content and bone density, improving the growth and development of bones in infants and young children during growth, promoting bone health, and is safe and has no side effects. In addition, in the composition, the specific type of oligosaccharide has a great influence on improving bone mineral content and improving bone density. Among them, 2'-fucosyllactose is compared with 3'-fucosyllactose or 6'-sialyl lactose, and the use of oligogalactose and 2'-fucosyllactose in combination can promote bone development and growth, and has higher bone mineral content and bone density.

[0060] The solutions of the present invention are not limited to the technical means disclosed by the above technical means, but also include technical solutions composed of any combination of the above technical features. The above is a specific implementation of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications are also regarded as the protection scope of the present invention.

Claims

1. A composition for improving bone density, characterized in that: include: 1,3-Dioleoyl-2-palmitoyl triglyceride, osteopontin and oligosaccharides.

2. The composition according to claim 1, characterized in that The mass ratio of 1,3-dioleyl-2-palmitoyl triglyceride, osteopontin and oligosaccharide is 100-200:0.5-20:

100.

3. The composition according to claim 2, characterized in that The mass ratio of 1,3-dioleyl-2-palmitoyl triglyceride, osteopontin and oligosaccharide is 100-200:0.5-10:

100.

4. The composition according to claim 1, characterized in that The oligosaccharide is galacto-oligosaccharide and 2'-fucosyllactose in a mass ratio of 1-2:

1.

5. The composition according to claim 1, characterized in that The composition further comprises at least one of unsaturated fatty acids, vitamins, minerals, proteins, fats, carbohydrates and functional additives.

6. The composition according to claim 5, characterized in that The functional additives include at least one of folic acid, niacin, pantothenic acid, biotin, choline, inositol, taurine, L-carnitine, and nucleotides.

7. The composition according to claim 5, characterized in that The unsaturated fatty acid includes at least one of docosahexaenoic acid, eicosatetraenoic acid, linolenic acid and α-linolenic acid.

8. The composition according to claim 5, characterized in that The vitamins include vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B 12 , vitamin C and at least one of them.

9. The composition according to claim 5, characterized in that The minerals include at least one of sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, iodine, chlorine and selenium.

10. Use of the composition for improving bone density according to any one of claims 1 to 9 in the preparation of a product for promoting bone development.

11. The use according to claim 10, characterized in that The promoting bone development is to increase bone density.

12. The use according to claim 10, characterized in that The product is food or medicine.

13. The use according to claim 10, characterized in that The products include nutritional supplements, solid beverages, and milk powder.

14. A product for promoting bone development, characterized in that: A composition comprising the composition for improving bone density according to any one of claims 1 to 9.

Images